SCHEMBL30923121

SCHEMBL30923121

OCc1c(Cl)cc2c(cnn2C2CCCCO2)c1Br

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ RXRA P19793 1/20 0.42
▸ RXRB P28702 1/20 0.42
▸ RXRG P48443 1/20 0.42
▸ CYP4F2 P78329 3/20 0.36
▸ CYP4A11 Q02928 3/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ DGAT2 Q96PD7 1/20 0.34
▸ ATR Q13535 2/20 0.33
▸ RET P07949 1/20 0.32
▸ PDE9A O76083 1/20 0.31
▸ PDE4D Q08499 1/20 0.31
▸ PDE1A P54750 2/20 0.30
▸ PDE1B Q01064 2/20 0.30
▸ PDE1C Q14123 2/20 0.30
▸ YTHDC1 Q96MU7 1/20 0.30
▸ CYP1A2 P05177 1/20 0.30
▸ HPGD P15428 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30922456 0.91 RXRA (0.41) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL31127858 0.90 RXRA (0.41) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL30922464 0.89 RXRA (0.40) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL27300174 0.88 RXRA (0.39) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL31642955 0.88 RXRA (0.39) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL30922966 0.87 RXRA (0.39) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL30922740 0.87 RXRA (0.38) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL30922810 0.86 RXRA (0.46) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL31642674 0.86 RXRA (0.38) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL30922816 0.86 RXRA (0.38) RXRARXRBRXRGCYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4598921-A1 MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE Amgen Inc. (US) 2025-08-13 — — EP disclosed
WO-2025136346-A1 INDAZOLE CONTAINING COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2025-06-26 — — WO disclosed
WO-2024107686-A1 MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE AMGEN INC. (US) 2024-05-23 — — WO disclosed
Send feedback